Lifecore Biomedical (LFCR) AI Stock Analysis

• Market Cap: $281.68M
• Dividend Yield: N/A
• Average Volume (3M): 117.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: 0.47%
• EPS Growth: -430.88%
• Country: US
• Employees: 524
• Sector: Healthcare
• Sector Strength: 53
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.06
• Shares Outstanding: 37,407,920
• 10 Day Avg. Volume: 120,475
• 30 Day Avg. Volume: 117,694
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.49
• Enterprise Value/Revenue: 3.21
• Enterprise Value/Gross Profit: 9.61
• Enterprise Value/Ebitda: -38.12
• 1Y Price Target: $8.75
• Price Target Upside: 16.20% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 49 Neutral
• Price Target: $7.50 ▼(-0.40% Downside)

Lifecore Biomedical's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue, high leverage, and negative cash flow. Technical analysis provides some support, but valuation remains poor due to negative earnings. The earnings call offers a glimmer of hope with strategic initiatives, but significant financial challenges persist.

Positive Factors

Strategic Expansion

Lifecore Biomedical is focusing on the fast-growing fill/finish segment of the contract development and manufacturing market, benefiting from growth in biologics and GLP-1s.

Technological Advancements

The company's new 5 head filler technology has more than doubled unit capacity and supports significant potential annual revenue, indicating Lifecore's commitment to state-of-the-art technology.

Negative Factors

Leverage Concerns

Maintaining LFCR shares at a MARKET PERFORM due to Lifecore’s significant leverage and valuation.

Revenue Delays

The anticipated ramp in revenue for Lifecore Biomedical may not occur until fiscal year 2027.

Lifecore Biomedical Business Overview & Revenue Model

Company Description

Lifecore Biomedical (LFCR) is a leading biotechnology company specializing in the development and manufacturing of high-quality hyaluronic acid-based products. The company operates primarily in the healthcare sector, focusing on regenerative medicine, medical devices, and pharmaceutical applications. Lifecore's core offerings include a range of injectable dermal fillers, surgical lubricants, and viscoelastic products that serve various medical needs, particularly in orthopedics and aesthetics.

How the Company Makes Money

Lifecore Biomedical generates revenue through multiple streams, primarily driven by the sale of its specialized hyaluronic acid products to healthcare providers and distributors. The company has established significant partnerships with medical device companies and pharmaceutical firms, allowing it to leverage its manufacturing capabilities for contract development and manufacturing services (CDMO). This collaboration not only enhances Lifecore's product offerings but also contributes to consistent revenue through service contracts. Additionally, the company benefits from a growing demand for its aesthetic products, particularly in the cosmetic dermatology market, as consumer interest in non-surgical treatments continues to rise.

Lifecore Biomedical Financial Statement Overview

Summary

Lifecore Biomedical's financials show modest revenue growth but are hampered by significant profitability and leverage issues. High debt and negative equity raise concerns about sustainability, despite some cash flow improvements.

Income Statement

Lifecore Biomedical's TTM revenue shows modest growth over the previous year, but profitability remains a concern. The company exhibits a negative EBIT and net profit margin, indicating operational challenges. Despite a slight revenue increase, the negative margins highlight potential inefficiencies or cost management issues.

Balance Sheet

The balance sheet reflects high leverage with a substantial debt-to-equity ratio, exacerbated by negative equity in the TTM period. The company's liabilities surpass assets, posing significant financial risks and limiting financial flexibility. The return on equity is not meaningful due to negative equity, which is a red flag for potential investors.

Cash Flow

While Lifecore Biomedical's operating cash flow has improved in the TTM period, the free cash flow remains negative due to high capital expenditures. The operating cash flow to net income ratio is positive, indicating some operational cash generation despite net losses. However, the persistent negative free cash flow suggests ongoing capital strain.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	130.31M	128.87M	128.26M	103.27M	111.27M	100.87M
Gross Profit	43.59M	40.30M	41.85M	27.98M	39.07M	38.94M
EBITDA	-10.99M	-38.72M	35.60M	-35.98M	14.23M	7.52M
Net Income	-44.65M	-38.72M	12.01M	-99.56M	-116.72M	-32.66M
Balance Sheet
Total Assets	237.69M	239.34M	273.70M	255.15M	295.44M	502.92M
Cash, Cash Equivalents and Short-Term Investments	5.42M	8.27M	8.46M	19.09M	991.00K	1.16M
Total Debt	130.34M	132.17M	130.36M	112.74M	247.78M	215.86M
Total Liabilities	235.46M	191.91M	219.80M	256.99M	187.30M	300.14M
Stockholders Equity	2.23M	47.43M	53.90M	35.09M	108.14M	202.78M
Cash Flow
Free Cash Flow	-10.74M	-13.62M	-18.14M	-55.22M	-52.53M	-8.75M
Operating Cash Flow	3.21M	-206.00K	-217.00K	-34.46M	-24.40M	15.02M
Investing Cash Flow	-6.96M	-6.42M	-17.92M	-4.81M	81.77M	-12.31M
Financing Cash Flow	6.09M	6.42M	7.51M	39.70M	-57.02M	-3.42M

Lifecore Biomedical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.53
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFCR, the sentiment is Positive. The current price of 7.53 is above the 20-day moving average (MA) of 7.49, below the 50-day MA of 7.64, and above the 200-day MA of 6.87, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 50.13 is Neutral, neither overbought nor oversold. The STOCH value of 47.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LFCR.

Lifecore Biomedical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EBS	61 Neutral	$407.07M	3.09	30.24%	―	-22.74%	―
ESPR	60 Neutral	$510.11M	―	23.44%	―	-3.48%	36.57%
DERM	56 Neutral	$185.75M	―	-57.22%	―	-27.40%	-475.41%
AQST	56 Neutral	$612.13M	―	77.48%	―	-24.38%	-94.72%
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
LFCR	49 Neutral	$281.68M	―	-76.41%	―	0.47%	-430.88%
TKNO	49 Neutral	$226.90M	―	-27.74%	―	11.40%	56.25%

Lifecore Biomedical Corporate Events

Lifecore Biomedical Strengthens Financial Position with Key Moves

Lifecore Biomedical, Inc. has strategically amended its asset-based lending revolving credit facility with BMO, extending the term by three years to 2027 and reducing interest rates. This move, alongside a recent $24.3 million private placement, significantly strengthens Lifecore’s financial position and supports its growth strategy in the expanding CDMO market. The company is enhancing its capabilities with new management, advanced manufacturing equipment, and new customer agreements.

Lifecore Biomedical Plans Strategic Growth and Transformation

Lifecore Biomedical, Inc., a leader in complex injectables, is poised for sustainable growth with a strategic plan to achieve over 12% revenue CAGR and 25%+ EBITDA margins. The company is leveraging its robust capabilities and experienced management team to capitalize on market opportunities, aiming to support $300 million in annual revenue. Lifecore’s transformation into a standalone CDMO with enhanced technical and regulatory strengths positions it as a compelling player in the financial markets.